A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)
Primary Objective
This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
Description
You are being asked to be in this research study because you have Synovial Sarcoma that has grown or not responded to treatment, and you completed the Pre-screening tests for this study. Your blood tested positive for certain proteins and your cancer cells tested positive for protein. The study involves taking certain types of immune cells from your blood, called T cells, and changing them in a laboratory before putting them back into your bloodstream, in order to help them to attack and kill cancer cells. This study plans to learn more about if the genetically changed T cells are safe and work to kill your cancer cells.
Details
Locations
University of Colorado Hospital
Principal Investigator
Breelyn Wilky
Study ID
Protocol Number: 19-0967
More information available at ClinicalTrials.gov: NCT04044768
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers